HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoshitaka Narita Selected Research

Terminal Care (Care, Terminal)

12/2020Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan.
10/2009[A survey of neurosurgeons' policies and attitudes regarding the disclosure of a diagnosis of glioma and the decision to pursue end-of-life care in glioma patients].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoshitaka Narita Research Topics

Disease

72Neoplasms (Cancer)
11/2022 - 11/2002
57Glioblastoma (Glioblastoma Multiforme)
11/2022 - 11/2002
47Glioma (Gliomas)
06/2022 - 09/2005
24Brain Neoplasms (Brain Tumor)
02/2022 - 09/2005
15Neoplasm Metastasis (Metastasis)
07/2019 - 04/2005
11Astrocytoma (Pilocytic Astrocytoma)
07/2021 - 09/2010
8Germinoma
01/2022 - 01/2010
8Lymphoma (Lymphomas)
11/2021 - 07/2010
6Breast Neoplasms (Breast Cancer)
07/2019 - 11/2008
5Oligodendroglioma
10/2020 - 01/2015
4Meningioma (Meningiomas)
02/2022 - 06/2013
4Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
01/2022 - 12/2010
3Sarcoma (Soft Tissue Sarcoma)
01/2022 - 12/2012
3Lymphopenia (Lymphocytopenia)
12/2021 - 01/2011
2Carcinogenesis
06/2022 - 12/2017
2Residual Neoplasm
05/2022 - 01/2013
2Melanoma (Melanoma, Malignant)
01/2022 - 09/2021
2Disease Progression
12/2021 - 02/2013
2Brain Edema (Cerebral Edema)
01/2021 - 01/2015
2Ependymoma
01/2021 - 12/2018
2Intracranial Hemorrhages (Intracranial Hemorrhage)
12/2018 - 06/2013
2Necrosis
12/2016 - 06/2013
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2013 - 12/2012
2Hematologic Neoplasms (Hematological Malignancy)
10/2013 - 09/2010
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
10/2013 - 09/2010
2Venous Thromboembolism
06/2013 - 10/2012
2Hypertension (High Blood Pressure)
06/2013 - 10/2012
2Leukemia
12/2012 - 09/2010
2Hepatitis
01/2012 - 01/2011
1Testicular Neoplasms (Testicular Cancer)
01/2022
1Ischemic Stroke
12/2021
1Transient Ischemic Attack
12/2021
1Thrombocytopenia (Thrombopenia)
12/2021

Drug/Important Bio-Agent (IBA)

26Temozolomide (Temodar)FDA LinkGeneric
05/2022 - 09/2010
15Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
06/2022 - 03/2012
9Bevacizumab (Avastin)FDA Link
05/2022 - 10/2012
8ErbB Receptors (EGF Receptor)IBA
12/2021 - 11/2002
8RNA (Ribonucleic Acid)IBA
01/2021 - 06/2015
6DNA (Deoxyribonucleic Acid)IBA
05/2022 - 10/2012
6Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2010
6Pharmaceutical PreparationsIBA
01/2021 - 11/2012
5MethyltransferasesIBA
05/2022 - 10/2012
5Telomerase (Telomerase Reverse Transcriptase)IBA
02/2022 - 08/2013
5Biomarkers (Surrogate Marker)IBA
01/2021 - 07/2010
5Biological ProductsIBA
08/2019 - 11/2008
4Messenger RNA (mRNA)IBA
10/2020 - 01/2014
4SteroidsIBA
11/2012 - 04/2005
3O-(6)-methylguanineIBA
05/2022 - 10/2012
3eribulinFDA Link
02/2022 - 07/2018
3Lomustine (CCNU)FDA Link
11/2021 - 01/2013
3NimustineIBA
11/2021 - 02/2013
3Progesterone Receptors (Progesterone Receptor)IBA
01/2019 - 11/2008
3Genetic Markers (Genetic Marker)IBA
04/2018 - 10/2013
3Procarbazine (Matulane)FDA Link
01/2018 - 01/2013
3Methotrexate (Mexate)FDA LinkGeneric
10/2017 - 07/2010
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2016 - 10/2012
3amsonic acid (DAS)IBA
01/2015 - 10/2012
3Monoclonal AntibodiesIBA
06/2013 - 09/2005
3TOR Serine-Threonine KinasesIBA
09/2011 - 11/2010
3epidermal growth factor receptor VIIIIBA
08/2010 - 01/2004
2AntigensIBA
11/2022 - 01/2022
2Protein Subunit VaccinesIBA
11/2022 - 01/2011
2alpha-hydroxyglutarateIBA
06/2022 - 11/2021
2Immune Checkpoint InhibitorsIBA
01/2022 - 01/2021
2Reactive Oxygen Species (Oxygen Radicals)IBA
09/2021 - 01/2014
2Tumor Biomarkers (Tumor Markers)IBA
01/2021 - 12/2019
2AntibodiesIBA
01/2021 - 09/2005
2Transcription Factors (Transcription Factor)IBA
01/2021 - 12/2017
2MicroRNAs (MicroRNA)IBA
12/2019 - 01/2019
2Antineoplastic Agents (Antineoplastics)IBA
07/2019 - 07/2018
2Peptides (Polypeptides)IBA
01/2019 - 01/2011
2CholesterolIBA
07/2018 - 01/2018
2Vincristine (Oncovin)FDA LinkGeneric
01/2018 - 01/2013
2ChromatinIBA
12/2017 - 01/2014
2GadoliniumIBA
05/2016 - 08/2012
2Estrogen ReceptorsIBA
11/2013 - 11/2008
2Alkylating AgentsIBA
10/2013 - 09/2010
2TransferasesIBA
10/2013 - 01/2012
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
09/2011 - 11/2010
2Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
09/2011 - 11/2002
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
09/2011 - 11/2010
1EpitopesIBA
11/2022
1Coloring Agents (Dyes)IBA
02/2022
1Glial Fibrillary Acidic ProteinIBA
01/2022
1S100 Proteins (S 100 Protein)IBA
01/2022
1Tissue Plasminogen Activator (Alteplase)FDA Link
12/2021
1Carboxylic AcidsIBA
12/2021
1depatuxizumab mafodotinIBA
12/2021
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
12/2021
1Immunoconjugates (Immunoconjugate)IBA
12/2021
1Alanine Transaminase (SGPT)IBA
12/2021

Therapy/Procedure

44Radiotherapy
06/2022 - 04/2005
34Drug Therapy (Chemotherapy)
06/2022 - 09/2005
28Therapeutics
07/2022 - 12/2008
16Chemoradiotherapy
05/2022 - 01/2010
4Aftercare (After-Treatment)
12/2021 - 01/2012
3Re-Irradiation
05/2022 - 01/2021
3Craniotomy
06/2021 - 02/2013
2Terminal Care (Care, Terminal)
12/2020 - 10/2009
2Adjuvant Chemotherapy
10/2018 - 02/2013